CD38 and Miyoshi myopathy: Assessing cilta-cel efficacy and safety in patients who had progressive MM after 1-3 prior LOT and were refractory to lenalidomide (Cohort A), early relapse after initial therapy (cohort B), r/r MM after PI, anti-CD38 antibody, an IMiD, and BCMA-directed treatment (cohort C), Less than CR after ASCT front-line therapy (cohort D), NDMM with the high-risk disease after no or only one cycle of prior therapy (cohort E), NDMM with standard-risk (ISS stage I and II) and after initiation of therapy (cohort F)